BioTuesdays

Tag - Daina Graybosch

F-star Therapeutics logo

SVB Leerink starts F-Star Therapeutics at OP; PT $39

SVB Leerink launched coverage of F-Star Therapeutics (NASDAQ:FSTX) with an “outperform” rating and $39 price target. The stock closed at $7.34 on July 7. F-star’s pipeline generates drug candidates that work with...

iTeos Logo

SVB Leerink starts iTeos Therapeutics at OP; PT $36

SVB Leerink launched coverage of iTeos Therapeutics (NASDAQ:ITOS) with an “outperform” rating and $36 price target. The stock closed at $32.92 on Aug. 18. “Though the stock has rallied since the IPO, we see potential...

Compugen Logo

SVB Leerink starts Compugen at OP; PT $15

SVB Leerink launched coverage of Compugen (NASDAQ:CGEN) with an “outperform” rating and $15 price target. The stock closed at $13.22 on May 6. “TIGIT / PVRIG could be the next evolution in immune checkpoint blockade...

Genocea Biosciences

SVB Leerink starts Genocea Biosciences at OP; PT $7

SVB Leerink launched coverage of Genocea Biosciences (NASDAQ:GNCA) with an “outperform” rating and price target of $7. The stock closed at $2.24 on Nov. 14. “Our positive view is based on the promise of Genocea’s ATLAS...

Innate Pharma Logo

SVB Leerink starts Innate Pharma at OP; PT $10

SVB Leerink initiated coverage of Innate Pharma (NASDAQ:IPHA) with an “outperform” rating and $10 price target. The stock closed at $6.31 on Nov. 8. Innate is a commercial stage biotech company focused on developing and...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.